Phase I Trial of TPI 287 as a Single Agent and in Combination with Temozolomide (TMZ) in Patients with Refractory or Recurrent Neuroblastoma (NB) or Medulloblastoma (MB)

Saulnier Sholler G, Eslin D, Roberts W, Kaplan J, Bergendahl G, Higgins T, Ashikaga T, Lenox S, Silberman S, Ferguson W. Phase I Trial of TPI 287 as a Single Agent and in Combination with Temozolomide (TMZ) in Patients with Refractory or Recurrent Neuroblastoma (NB) or Medulloblastoma (MB)  June 2011 ASCO Annual Meeting, Chicago, IL